Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the current market size of the live attenuated polio vaccine industry, and what growth rate is it expected to achieve?
The live attenuated polio vaccine market size has grown strongly in recent years. It will grow from $1.85 billion in 2024 to $2.00 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to mass immunization campaigns, the emergence of vaccine-derived poliovirus concerns, government immunization programs, public awareness and education, and vaccine accessibility and affordability.
The live attenuated polio vaccine market size is expected to see strong growth in the next few years. It will grow to $2.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to improved vaccine stability and shelf life, a resurgence of polio cases in conflict zones, donor fatigue in eradication efforts, expansion of routine immunization programs, and increased R&D for safer live attenuated vaccine strains. Major trends in the forecast period include the emergence of vaccine-derived poliovirus, the development of oral polio vaccine, technological advancements in vaccine formulations, the integration of digital technologies, and public-private partnerships.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24280&type=smp
What are the major drivers contributing to the growth of the live attenuated polio vaccine market?
The expansion of immunization programs is expected to propel the growth of the live attenuated polio vaccine market going forward. Immunization programs refer to organized efforts by governments, health organizations, or other institutions to provide vaccines to populations to prevent the spread of infectious diseases. The expansion of immunization programs is primarily due to increased global awareness of the importance of disease prevention and strong support from governments, international health organizations, and funding bodies. Immunization programs support the live attenuated polio vaccine (LAPV) by ensuring widespread distribution, safe administration, and high coverage to build herd immunity, prevent virus transmission, and aid in global polio eradication. For instance, in October 2023, according to the Centers for Disease Control and Prevention, a US-based national public health agency, between 2021 and 2022, global coverage for the first dose of the diphtheria-tetanus-pertussis (DTP) vaccine rose from 86% to 89%. Therefore, the expansion of immunization programs is driving the growth of the live attenuated polio vaccine market.
What are the major market segments driving the growth of the live attenuated polio vaccine industry?
The live attenuated polio vaccine market covered in this report is segmented –
1) By Vaccine Type: Monovalent, Bivalent, Trivalent
2) By Administration Route: Oral Administration, Intramuscular Injection, Subcutaneous Injection
3) By Age Group: Infants (0-1 years), Children (1-5 years), Adults (Above 5 years)
4) By End-User: Hospitals, Clinics, Public Health Agencies, Other End-Users
Subsegments:
1) Monovalent: mOPV1 For Serotype 1
2) Bivalent: Type 1, Type 3
3) Trivalent: Poliovirus Type 1, Poliovirus Type 2, Poliovirus Type 3
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/live-attenuated-polio-vaccine-global-market-report
What are the key trends shaping the live attenuated polio vaccine market in the forecast period?
Major companies operating in the live attenuated polio vaccine market are focusing on obtaining regulatory approvals to ensure their vaccines meet the safety and efficacy standards required by health authorities globally. Regulatory approvals refer to the formal authorization granted by government health agencies or regulatory bodies, allowing a product, such as a vaccine, to be marketed, sold, and used within a specific region or country. For instance, in July 2024, Biological E, an India-based pharmaceutical and biologics company, received approval from the World Health Organization (WHO) for its novel oral polio vaccine type 2 (nOPV2), a next-generation live, attenuated oral vaccine designed to address the challenges associated with traditional oral polio vaccines. This next-generation vaccine is designed to combat circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks more effectively than its predecessor. nOPV2 is engineered with enhanced genetic stability, reducing the risk of the vaccine virus reverting to a virulent form, which has been a concern with older vaccines.
Who are the key market players contributing to the growth of the live attenuated polio vaccine industry?
Major companies operating in the live attenuated polio vaccine market are Sanofi Pasteur, GlaxoSmithKline plc, LG Chem Ltd., Serum Institute of India Pvt. Ltd., Biological E. Limited, Indian Immunologicals Limited, Sinovac Biotech Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Vabiotech, Emergent BioSolutions Inc., Valneva SE, Bio Farma, PT Bio Farm, Bilthoven Bio, Panacea Biotec, Haffkine Biopharmaceutical, Panacea Biotec Ltd., Zydus Cadila, Liaoning Cheng Da Biotechnology Co.Ltd, Bharat Biotech International Limited
Which regions are leading the growth of the live attenuated polio vaccine market globally?
North America was the largest region in the live attenuated polio vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated polio vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Live Attenuated Polio Vaccine Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24280&type=smp
Need Customized Data On Live Attenuated Polio Vaccine Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24280&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
